Zhukova Olga V, Kovaleva Tatiana F, Arkhipova Evgenia V, Ryabov Sergey A, Mukhina Irina V
Department of Pharmaceutical Technology, Privolzhsky Research Medical University, Nizhny Novgorod 603005, Russia.
Department of Molecular and Cellular Technologies, Privolzhsky Research Medical University, Nizhny Novgorod 603005, Russia.
Biomed Rep. 2020 Nov;13(5):47. doi: 10.3892/br.2020.1354. Epub 2020 Aug 28.
The aim of the present study was to evaluate the current body of knowledge regarding tumor-associated macrophages (TAMs) and their potential use in antitumor therapy, based on their role in the pathological process of tumorigenesis. For this purpose, a critical analysis of published data and summarization of the findings available from original studies, focusing on the role of TAMs in the pathological process, and their potential therapeutic application was performed. Promising key avenues of research were identified in this field. The following issues seem the most promising and thus worth further investigation: i) The process of M1/M2 macrophage polarization, macrophage characteristics at intermediate polarization steps and their role in the tumor process; ii) determining the conditions necessary for transitions between the M1 and M2 macrophage phenotypes and the role of signals from the microenvironment in this process; iii) cause-and-effect associations between the quantity and quality of macrophages, and the prognosis and outcome of the pathological process; iv) modulation of macrophages and stimulation of their phagocytic activity with drugs; v) targeted vector-based systems for drug delivery to macrophages; and vi) targeted drug delivery systems with macrophages as carriers, thus potentially combining chemotherapy and immunotherapy.
本研究的目的是基于肿瘤相关巨噬细胞(TAMs)在肿瘤发生病理过程中的作用,评估目前关于TAMs的知识体系及其在抗肿瘤治疗中的潜在用途。为此,对已发表的数据进行了批判性分析,并总结了原始研究中的发现,重点关注TAMs在病理过程中的作用及其潜在的治疗应用。在该领域确定了有前景的关键研究途径。以下问题似乎最具前景,因此值得进一步研究:i)M1/M2巨噬细胞极化过程、中间极化步骤的巨噬细胞特征及其在肿瘤过程中的作用;ii)确定M1和M2巨噬细胞表型之间转换所需的条件以及微环境信号在此过程中的作用;iii)巨噬细胞的数量和质量与病理过程的预后和结果之间的因果关系;iv)用药物调节巨噬细胞并刺激其吞噬活性;v)基于靶向载体的巨噬细胞药物递送系统;以及vi)以巨噬细胞为载体的靶向药物递送系统,从而有可能将化疗和免疫疗法结合起来。